US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Annexin Pharmaceuticals will present at the BioStock Life Science Summit, November 21

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Anders Haegerstrand will present Annexin Pharmaceuticals to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: 21 November Time: 11:20 Location: Auditorium at Medicon

BioStock: Annexin: Could ANXV replace anti-VEGFs?

Annexin Pharmaceuticals is developing the drug candidate ANXV in the eye disease retinal vein occlusion, RVO, as well as in cancer. Recently, the company released phase IIa topline results from its study in RVO. Annexin visited BioStock’s studio to talk more about the results and the plan going forward.– The results are as good as we could have ever hoped for, says CEO Anders Haegerstrand.Watch the interview with CEO Anders Haegerstrand and CMO/CSO Anna Frostegård at biostock.se:https://www.biostock.se/en/2024/08/annexin-pharmaceuticals-could-anxv-replace-anti-vegfs/This is a press

BioStock: Annexin comments on acquisition and focus on ANXV in ophthalmology

Merck recently announced that they are acquiring the biotech company EyeBio for up to 3 billion USD, thereby strengthening its presence in ophthalmology. EyeBio’s drug candidate Restoret is being developed to treat diabetes-related eye diseases. Another active player in the ophthalmology field is the Swedish company Annexin Pharmaceuticals. BioStock reached out to the company’s CEO Anders Haegerstrand to get his comments on the acquisition and gain further insights into Annexin’s focus for 2024.Read the full article at biostock.se : https://www.biostock.se/en/

BioStock: Annexin's phase II study fully recruited with positive signals

Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.Read the article about Annexin Pharmaceuticals here: https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/ 

BioStock: Annexin towards completion of phase II study and share issue

After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment.Read the interview with CEO Anders Haegerstrand here: https://www.biostock.se/en/2024/04/annexin-towards-completion-of-phase-ii-study-and-

BioStock: Strong start for Annexin in 2024

Annexin Pharmaceuticals had a successful 2023, and the new year seems to be starting with continued success. Positive signals of effect have now been observed in the majority of patients treated in the phase II study in retinal vein occlusion. Additionally, the company emerged strengthened from an oversubscribed rights issue that added SEK 35.6 million at the turn of the year. BioStock reached out to CEO Anders Haegerstrand for a comment.Read the article about Annexin Pharmaceuticals here: https://www.biostock.se/en/2024/02/strong-start-for-annexin-in-2024/ This is a press release

First patient treated in the second dose group in Annexin's RVO study

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company's clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No limiting treatment-related side effects have been reported and the company has received recommendation to proceed with treatment of patients in the next dose group. An expected accelerated recruitment rate means that last patient in is planned to the first quarter of 2024.“It is very gratifying that we see continued progress in this

Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting

NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG-KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN ANNEXIN PHARMACEUTICALS AB IN ANY JURISDICTION.  SEE THE SECTION “IMPORTANT INFORMATION” BELOW. The Board of Directors of Annexin Pharmaceuticals AB (publ) ("Annexin" or the “

BioStock: Annexin’s CSO on progress in cancer initiative

One of Annexin Pharmaceuticals’ important achievements lately is having created a conjugate of the drug candidate ANXV. By binding the candidate to a chemotherapy agent, the goal is to eventually offer a cancer treatment with a new mechanism of action where effective treatments are currently lacking. BioStock contacted the company’s CSO/CMO and co-founder Anna Frostegård to know more about the importance and the plans going forward.Read the interview with Annexin Pharmaceuticals' CSO/CMO and co-founder Anna Frostegård here: https://www.biostock.se/en/2023/10/annexins-cso-on-progress-in-

Annexin announces success in the company's cancer initiative

Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule. In cell systems outside the body, this ANXV conjugate has been shown to kill a type of cancer cell taken from a person with triple-negative

BioStock Investor Meeting: Annexin Pharmaceuticals

Annexin Pharmaceuticals presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | Annexin Pharmaceuticals - YouTube  See the interview via:  BioStock Investor Meeting | Interview with Annexin | September 2023 - YouTube  This is a press release from BioStock - Connecting

Annexin presents at Redeye Investor Forum in Gothenburg on September 14

Annexin Pharmaceuticals AB today announced that the company is participating at Redeye Investor Forum in Gothenburg on September 14, 2023, 18:00-20:00 CET. CEO Anders Haegerstrand will present the latest development of the company, including the recently presented promising signals of effect in the company’s ongoing clinical RVO-study. The presentation and moderated Q&A session is broadcasted live via Redeye’s website www.redeye.se/events/ , where registration for in-person attendance at Hotel Pigalle, Södra Hamngatan 2A in

BioStock: Annexin’s CEO: “Our biggest success in a long time”

Annexin reported positive findings in the phase II study with ANXV in retinal vein occlusion, RVO, in August. This justifies the continuation of the study, which now follows a simplified design that is expected to accelerate patient recruitment. CEO Anders Haegerstrand explains more about the significance of the findings and the continued development within RVO in an interview with BioStock.Read the interview with Annexin Pharmaceuticals' CEO Anders Haegerstrand here: https://www.biostock.se/en/2023/09/annexins-ceo-our-biggest-success-in-a-long-time/ This is a press release from

Annexin presents at ProHearings on August 29

Annexin Pharmaceuticals AB today announced that the company is participating at ProHearings’ Capital Markets Day on August 29, 2023, at 09:10 CET. CEO Anders Haegerstrand will present the latest development of the company, including the recently presented promising signals of effect in the company’s ongoing clinical RVO-study. The presentation and moderated Q&A session is broadcasted live via organizer’s website www.prohearings.com, where registration for in-person attendance at the venue in central Stockholm also is available. The presentation will also be available at Annexin’s website

Promising signals of effect in Annexin's RVO-study

Annexin Pharmaceuticals AB today announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase 2-study in retinal vein occlusion with the investigational new drug ANXV. Positive findings justify an extended follow-up period.A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study. The evaluation confirmed an unexpectedly long duration of effect with a single dose of standard of care anti-VEGF treatment in two of five treated

BioStock Life Science Spring Summit with Annexin Pharmaceuticals

Do not miss Annexin Pharmaceuticals’s presentation at the BioStock Life Science Spring Summit, today May 30 at 12.00. The event starts at 10.00 - see the full programme on BioStock's website  or YouTube channel .CEO Anders Haegerstrand will present Annexin Pharmaceuticals at the BioStock Life Science Spring Summit , starting at 12.00.  This is a press release from BioStock - Connectin Innovation &

BioStock: Annexin’s CMO on study results and participation in ARVO

Biotech company Annexin Pharmaceuticals earlier announced encouraging first results in one of two studies evaluating the candidate ANXV in retinal vein occlusion. In the imaging study SIGHT, data from the first patient show that the candidate binds to the desired area and target molecule. The results provide support for the continued development of ANXV as a treatment for the disease. CMO/CSO and Co-founder Anna Frostegård tells BioStock more about the results and the ARVO congress that the company recently participated in.Read the interview with Annexin Pharmaceuticals' CMO/CFO and Co-

Annexin reports first imaging-study results in Retinal Vein Occlusion

Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient with RVO indicates site-specific accumulation of ANXV in the vessels affected by retinal vein occlusion.Annexin is collaborating with TRACER Europe BV (“TRACER”) and the University Medical Center Groningen (“UMCG”) on an innovative clinical molecular imaging trial. The trial, also referred to as the SIGHT study, uses Annexin’s fluorescently labelled drug candidate ANXV to visualize the

BioStock: One-on-one with Annexin Pharmaceuticals' new CFO

Biotech company Annexin Pharmaceuticals has had intensive months with the phase II study in RVO as well as investments in the cancer area. Most recently, the company announced that it had recruited Susanne Andersson as the new CFO and as part of the management team. BioStock spoke to Susanne in connection with her appointment today, to learn more about her background and expectations for the role at Annexin.Read the interview with Annexin Pharmaceuticals' new CFO Susanne Andersson here: https://www.biostock.se/en/2023/04/one-on-one-with-annexin-pharmaceuticals-new-cfo/ This is a press

Annexin Pharmaceuticals appoints Susanne Andersson as CFO

Annexin Pharmaceuticals AB (publ) has recruited Susanne Andersson as Chief Financial Officer (CFO).  Susanne will take position as CFO at Annexin Pharmaceuticals during April 2023, joining the management team. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines. Susanne’s most recent position was an interim assignment as CFO consultant on Team Interim.  “I want to thank the current CFO Henrik Palm, who will enter into

BioStock: Annexin Pharmaceuticals on the new indication cancer

In December, Annexin Pharmaceuticals revealed their plans to enter the cancer field with their candidate ANXV. In his visit to BioStock's studio, CEO Anders Haegerstrand sheds more light on the potential of the candidate in this new arena and whether the conditions for out-licensing have altered.Watch the interview (in Swedish) with Annexin Pharmaceuticals' CEO Anders Haegerstrand here:https://www.biostock.se/2023/03/annexin-pharmaceuticals-om-nya-indikationen-cancer/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Intense Q4 leads Annexin into interesting 2023

Intense and significant – that is how Annexin Pharmaceutical’s CEO Anders Haegerstrand describes the year 2022. Standing out is the company’s big leap forward with drug candidate ANXV within the serious vascular disease retinal vein occlusion. The year ended with the company also taking its first step into the cancer field, which opens up another exciting year.Read the article about Annexin Pharmaceuticals at biostock.se: https://www.biostock.se/en/2023/02/intense-q4-leads-annexin-into-interesting-2023/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Annexin's CEO: "The cancer area more than doubles the potential"

Annexin Pharmaceuticals' candidate ANXV is being developed as a new treatment for retinal vein occlusion, an eye disease that affects more than 16 million people globally. However, the candidate has also shown promising potential in cancer, among other indications, and the Stockholm-based company has recently stepped into the field. BioStock spoke with CEO Anders Haegerstrand to get his take on the potential for ANXV in cancer.Read the interview with Annexin Pharmaceuticals at biostock.se: https://www.biostock.se/en/2023/02/annexins-ceo-the-cancer-area-more-than-doubles-the-potential (

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe